The group's principal activity is to design, develop, market and support science and technology-based products and services intended to improve and accelerate the processes of drug discovery and chemical development. The group provides drug discovery services to pharmaceutical and biotechnology companies. The services are based on proprietary combinatorial chemistry and high-throughput screening technologies. Using proprietary technologies and processes, scientists identify and optimize novel drug candidates through research collaborations. The group's collaborative drug discovery is focused on the creation of new small molecule therapeutics.
